Multiple myeloma is an incurable plasma cell neoplasia characterized by the production of large amounts of monoclonal immunoglobulins.
Introduction
Multiple myeloma, a malignancy of plasma cells, results in the overproduction of monoclonal immunoglobulins. Although the hitherto existing therapeutic strategies, such as chemotherapy, radiotherapy, autologous, and allogeneic stem cell transplantation, lead to prolonged survival of multiple myeloma patients, these therapies rarely induce long-lasting complete remissions but frequently are associated with severe adverse effects (1) . Recently, the dipeptidyl boronic acid derivative bortezomib (PS-341, Velcade), a reversible, highly selective and potent inhibitor of the 26S proteasome, has been approved for treatment of multiple myeloma progressing on prior therapy (2, 3) . According to recent studies, bortezomib may also be part of very effective frontline therapy.
The 26S proteasome constitutes a multienzyme complex present in all eukaryotic cells that plays an essential role in degrading supernumerous, defective, or misfolded proteins, which are targeted for proteasomal degradation by ubiquitinylation. In addition, the proteasomes are involved in the regulation of cellular processes, including cell cycle and apoptosis, by controlling the degradation of key regulatory factors (4) . Bortezomib and other proteasome inhibitors induce apoptosis in many different types of cancer cells; however, myeloma cells seem to be exceptionally sensitive (5, 6) . 6 The molecular mechanisms of this hypersensitivity have not yet been fully characterized.
In general, it is believed that the antimyeloma effect of bortezomib is, at least partially, due to inhibition of the transcription factor nuclear factor-nB (NF-nB). Constitutive NF-nB activity in myeloma cells mediates survival as well as resistance to chemotherapy and radiotherapy (6, 7) , among other effects, by inducing the expression of antiapoptotic proteins, adhesion molecules, and autocrine growth factors such as interleukin-6 (IL-6; ref. 5) . NF-nB is normally sequestered in the cytoplasm as an inactive complex with inhibitory proteins called InBs. Activation of NF-nB requires signal-induced proteasome-dependent degradation of InBs, thereby releasing NF-nB that then activates transcription of its target genes (8) .
However, proteasome inhibitors may have additional effects on myeloma cells beyond the blockade of NF-nB because a specific inhibitor of the InB kinase h (IKKh) reduced proliferation of myeloma cells markedly less effectively than bortezomib (7) . In consistency, we also observed that myeloma cell lines were markedly more sensitive to bortezomib when compared with other, more specific NF-nB inhibitors.
Proteasome inhibition prevents the clearance of unfolded proteins by the endoplasmic reticulum (ER)-associated degradation pathway (ERAD), resulting in an ER stress response (9, 10) . This so-called unfolded protein response (UPR) is a signaling pathway from the ER to the nucleus triggered by the accumulation of misfolded proteins in the ER lumen (11, 12) . The UPR includes three mechanisms to handle the vast increase of unfolded proteins: transcriptional induction of target genes enhancing protein folding, general translational repression, and ERAD to eliminate misfolded proteins (13) . UPR activation seems to be essential for plasma cell differentiation and survival by inducing ER chaperones and folding enzymes. However, overwhelming ER stress activates terminal UPR, leading to apoptosis (14) (15) (16) (17) .
Based on these findings, we hypothesized that the proapoptotic effect of bortezomib in myeloma cells producing large amounts of secreted immunoglobulin is due to the accumulation of IgGderived defective ribosomal products (DRiPs) and other unfolded proteins in the ER and cytoplasm. Therefore, the level of ER proteins synthesized in cells should correlate with their sensitivity towards proteasome inhibition. To address this question, we investigated the effects of proteasome inhibitors, such as bortezomib, on the viability of myeloma cell clones producing various amounts of immunoglobulin. We found a clear correlation of the immunoglobulin chain expression level with the sensitivity towards proteasome inhibitors in subclones of the human IgGsecreting myeloma cell line JK-6L and in subclones of the murine myeloma cell line Ag8 transfected with an expression plasmid encoding the A heavy (H)-chain. Moreover, proapoptotic factors of the ER stress response were much stronger induced in subclones producing high levels of AH-chains than in those producing no AH-chains.
Materials and Methods
Antibodies. The following primary antibodies were used: monoclonal mouse anti-GRP78 (BiP, BD PharMingen, Heidelberg, Germany), rabbit polyclonal anti-actin (Sigma, Taufkirchen, Germany), rabbit polyclonal anticaspase-12 (Acris Antibodies GmbH, Hiddenhausen, Germany), rabbit polyclonal anti-XBP-1, mouse monoclonal anti-CHOP, rabbit polyclonal anti-Bcl-2, and mouse monoclonal anti-Bax (all from Santa Cruz Biotechnology, Santa Cruz, CA). As secondary antibodies, the following were used: horseradish peroxidase-conjugated goat anti-mouse IgG, goat anti-rabbit IgG (Amersham Biosciences, Freiburg, Germany), donkey antigoat IgG (Santa Cruz Biotechnology), FITC-conjugated goat anti-mouse IgM (Southern Biotechnology Associates, Birmingham, AL), and FITCconjugated goat anti-human IgG (Caltag, Burlingame, CA).
Reagents. MG-132, lactacystin, and MG-262 were received from Calbiochem (Schwalbach/Ts., Germany); bortezomib (PS-341, Velcade) was obtained from the University Hospital Pharmacy Erlangen; and tunicamycin was purchased from Sigma.
Cell lines and culture conditions. Cell lines used in this study were grown in RPMI 1640 supplemented with 50 units/mL penicillin, 50 Ag/mL streptomycin, 1 mmol/L sodium pyruvate, 2 mmol/L L-glutamine, 10% FCS for mouse myeloma cells, and 20% FCS for JK-6L. Cells were maintained at 37jC in a humidified incubator containing 5% CO 2 . We established the human myeloma cell line JK-6L from the peripheral blood of a patient with an IgGn secreting multiple myeloma (18, 19) . The Ag17A3.1 (Ag8AH) cell line was generated by transfection of Ag8.H cells, a subclone of the murine immunoglobulin-negative mouse plasmocytoma Ag8.653 (20) , with the AH-chain-encoding plasmid vector pAgptDsec. This vector contains the genomic sequence of a productively rearranged murine AH-chain gene harboring the 17.2.25 VH region, which is able to pair with immunoglobulin light chains (21) . The polyadenylated sequence of the secreted form was deleted. Stable transfectants were selected in complete RPMI supplemented with 2.5 Ag/mL mycophenolic acid, 250 Ag/mL xanthine, 100 Amol/L hypoxanthine, and 16 Amol/L thymidine (HT-media supplement; SigmaAldrich, Taufkirchen, Germany). To obtain Iga-expressing Ag8 cells (Ag8Iga), Ag8.H cells were transfected with an expression plasmid encoding murine Iga (22) . Single-cell clones from Ag8AH and JK-6L cells were established by limiting dilution.
Flow cytometric analysis. Surface staining was done as described (23) . For intracellular staining, cells were fixed and permeabilized using Cytofix/ Cytoperm (BD, Heidelberg, Germany), stained with the appropriate amount of antibodies, and analyzed by flow cytometry using a FACSCalibur (BD Biosciences, San Jose, CA). Data analyses were done using the Cell Quest software (BD Biosciences).
Viability assay. Cells (4 Â 10 4 ) were treated with different concentrations of proteasome inhibitors for 24 h and incubated for another 4 h with AlamarBlue (15 AL added to 200 AL of culture; BioSource International, Inc., Camarillo, CA). Activity of the mitochondrial dehydrogenase results in conversion of the coloring, which was followed by measurement of the absorption using a spectrophotometer (Spectramax 190, Molecular Devices, Sunnyvale, CA).
Cell cycle analysis. Cells (1 Â 10 5 ) were treated with 1 Amol/L bortezomib for indicated time intervals. Harvested cells were resuspended in a staining solution containing 0.6 Ag/mL propidium iodide (SigmaAldrich), 4 mmol/L sodium citrate, and 0.1% Triton X-100 and incubated for 24 h at 4jC. DNA content was determined by flow cytometry (Epics XL, Coulter Co., Miami, FL).
Cell death analysis. Cells (1 Â 10 5 ) were treated with different concentrations of bortezomib for indicated time intervals; 50 Amol/L of the broad-range caspase inhibitor zVAD-FMK (Alexis Biochemicals, San Diego, CA) was used to block caspase activation. Staining with Annexin V-FITC (Responsif GmbH, Erlangen, Germany) and propidium iodide (SigmaAldrich) was done as described (24) . The fluorescent dye 3,3 ¶-dihexyloxacarbocyanine iodide (DiOC 6 , Sigma) was used to reveal disruption of the mitochondrial transmembrane potential (DW m ). Immunoblotting. Cells (1 Â 10 6 ) were treated with 1 Amol/L bortezomib for indicated time intervals. Equal amounts of cells were washed with PBS and directly lysed in SDS sample buffer containing h-mercaptoethanol to generate total cell lysates. Proteins were separated on SDS-polyacrylamide gels and transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, MA). Membranes were blocked with 5% nonfat dry milk (Roth, Karlsruhe, Germany) in TBS solution containing 0.05% Tween 20 (Merck, Hohenbrunn, Germany) for 1 h. Blots were probed with antibodies and developed using the enhanced chemiluminescence method.
Reverse transcription-PCR analyses. Cells (1 Â 10 6 ) were treated with 1 Amol/L bortezomib for indicated time intervals. Total RNA was isolated using the Mini RNAeasy kit (Qiagen, Hilden, Germany). Aliquots of 1 Ag total RNA were treated with the Superscript reverse transcriptase (Invitrogen, Karlsruhe, Germany) and amplified with Taq polymerase (NEB, Frankfurt/Main, Germany) using specific primers for XBP-1 ( forward, CCTTGTGGTTGAGAACCAGG; reverse, TCTCTGTCTCAGAGGGGATC) and glyceraldehyde-3-phosphate dehydrogenase ( forward, AGTCCAGT-GAGCTTCCCGTTCAGC; reverse, TGGTATCGTGGAAGGACTCATGAC). PCR products were separated by electrophoresis on agarose gels and visualized by ethidium bromide staining. For quantitative real-time PCR analysis, the cDNA and appropriate primers (Bcl-2 forward,Electrophoretic mobility shift analysis. Electrophoretic mobility shift assays (EMSA) were done as described previously (25) . Briefly, nuclear extracts were prepared from cells (5 Â 10 6 ) treated with 1 Amol/L bortezomib for indicated time intervals. Ten micrograms of nuclear extracts were added to the probe mix. Probes were end labeled with 32 P-dGTP (Hartmann Analytik, Braunschweig, Germany). The reaction mixtures were incubated at room temperature for 15 min and run on a 4% non-denaturing polyacrylamide gel. For specificity control, nuclear extracts were incubated for 15 min at room temperature with unlabeled double-stranded oligonucleotides or a respective mutant variant at 100-fold molar excess. Gels were dried on Whatman paper and exposed to X-ray film for 48 h at À70jC. Alternatively, gels were analyzed using phosphoimaging instrumentation (Fujifilm FLA-3000, Agilent Technologies, Palo Alto, CA).
Metabolic labeling. For detection of IgG DRiPs, short-term pulse-chase experiments were conducted following previously published standard DRiP pulse-chase protocols (26, 27) . Briefly, JK-6L cells were treated with 25 Amol/L of each MG-132 and lactacystin or DMSO during 10 min of starvation in methionine-free, serum-free RPMI (Invitrogen, Life Technologies, Karlsruhe, Germany). Cells were radiolabeled for 5 min with 1.5 mCi/mL 35 S-methionine (Amersham Life Sciences, GE Healthcare, Munich, Germany) and chased for up to 30 min while shaking at 37jC in Iscove's DMEM supplemented with 10% FCS and 10 mmol/L methionine in the presence or absence of proteasome inhibitors. Cells were lysed in 200 AL CHAPSdeoxycholate buffer for 5 min on ice and separated from the insoluble fraction by centrifugation at 20,000 Â g for 10 min. IgG proteins were recovered from the soluble fraction by immunoprecipitation using antihuman IgG antibodies (mixture of polyclonal rabbit and goat anti-human IgGs from Jackson Immuno Research Laboratories, Inc., West Grove, PA) prebound to Protein G-Sepharose. Samples were separated by SDS-PAGE on a 10% Acrylamide Prosieve gel (FMC Bioproducts, Rockland, ME). Following fixation for 1 h in 40% methanol, 10% acetic acid, gels were rinsed with water, soaked in 1 mol/L sodium salicylic acid solution for 5 h, and dried. Radioactivity in gels was analyzed using phosphorimaging instrumentation (Fujifilm BAS-2000, Fujifilm, Tokyo, Japan) or fluorography.
Results
Sensitivity to bortezomib-induced apoptosis depends on immunoglobulin expression levels. First, we wanted to determine the sensitivity of myeloma cells secreting high versus low amounts of IgG towards proteasome inhibitors (Fig. 1A ). For this Figure 1 . Bortezomib reduces cell viability in immunoglobulin-expressing myeloma cell lines. A, experimental system used in this study. In a first approach, subclones of the human JK-6L cell line producing low (JK-6L.39L) and high (JK-6L.31H) levels of IgG were incubated in the presence (+) or absence (À) of proteasome inhibitors and analyzed for their viability. In a second approach, non-transfected (Ag8.H) and AH-chain-transfected (Ag8AH) murine Ag8 cells as well as AgAH subclones without (Ag8AHÀ, clone Ag8AH.12) or with (Ag8AH+, clone Ag8AH.1) AH-chain expression were analyzed for their viability in the presence or absence of proteasome inhibitors. B, flow cytometric analyses of cytoplasmic IgG in JK-6L and cytoplasmic AH-chain expression in the parental Ag8AH clone and its subclones Ag8AH+ (Ag8AH.1) and Ag8AHÀ (Ag8AH.12). Numbers in histograms represent the mean fluorescence intensity of IgG expression in JK-6L subclones and the percentages of AH-chain-positive Ag8 cells. Histograms representing flow data of Ag8AH, Ag8AHÀ, and Ag8AH+ cells (filled histograms ) and Ag8.H (non-filled histograms ) are overlaid. C, cell viability assays of human JK-6L subclones (JK-6L.39L and JK-6L.31H) and murine Ag8 cell lines (Ag8.H, Ag8AH, and Ag8Iga). Cells were treated with different concentrations of bortezomib as indicated for 24 h and incubated with the vital dye AlamarBlue. The absorbance (OD ) was measured using a spectrophotometer. Columns, mean values from triplicates; bars, SD. Represent one of three independently done experiments. Student's t test was used for statistical analysis. **, P V 0.01; *, P V 0.05.
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www.aacrjournals.org purpose, we tested >500 subclones of the human myeloma cell line JK-6L, which naturally secretes IgG, for the levels of intracellular IgG expression by flow cytometry. The maximal difference between IgG-producing cells was up to 5-fold (Fig. 1B) . Selected subclones producing different amounts of IgG were treated with increasing concentrations of proteasome inhibitors, and viability was determined. As shown in Fig. 1C , the viability of a high (JK-6L.31H) and a low (JK-6L.39L) IgG-producing subclone was strongly and dose-dependently reduced by concentrations of bortezomib as low as 10 nmol/L. However, the subclone producing higher levels of IgG was significantly more affected by proteasome inhibition, although the difference in IgG synthesis was at the most 5-fold. Similar results were obtained for other high and low IgGproducing JK-6L subclones (data not shown). The correlation between IgG expression and sensitivity towards proteasome inhibition was also observed using another proteasome inhibitor (MG-262) that reversibly blocks the proteasome by a different mechanism (data not shown).
To further challenge our hypothesis that the level of immunoglobulin biosynthesis determines the sensitivity towards proteasome inhibition, we established an in vitro model, based on the murine myeloma cell line Ag8, which express neither endogenous immunoglobulin heavy (H) nor light (L) chains (Fig. 1A) . The Ag8.H cells were transfected with an expression plasmid encoding the membrane form of a AH-chain (Fig. 1A) ; hence, this AH-chain cannot be secreted. Due to the lack of IgL chains, there is also no surface expression detectable. Expression of AH-chain was analyzed by flow cytometry (Fig. 1B) and Western blot analysis using an anti-IgM antibody (data not shown). The viability of Ag8 cells synthesizing AH-chains (Ag8AH) was drastically reduced with increasing proteasome inhibitor concentrations, whereas the nontransfected parental cells (Ag8.H) seemed virtually unaffected by the proteasome inhibitor (Fig. 1C) . In addition, expression of another ER-synthesized protein Iga, which is a signal transducing component of the B-cell receptor complex, rendered Ag8 cells hypersensitive towards bortezomib (Fig. 1C) . These results clearly indicate that the sensitivity of myeloma cells towards proteasome inhibitors depends on the synthesis of immunoglobulin chains or other proteins processed within the ER.
To exclude artifacts caused by the transfection and selection procedure, we generated subclones of Ag8AH cells to obtain clones with and without AH-chain expression (Fig. 1A) . In Fig. 1A , flow cytometric analyses of AH-chain expression of two Ag8AH subclones, one that lost AH-chain expression (Ag8AHÀ) and one that still expressed the AH-chain (Ag8AH+), are displayed.
To exclude the possibility of differences in proteasome function between Ag8AHÀ and Ag8AH+ subclones, we determined the proteasomal chymotrypsin-like activity. Because proteasomal proteolysis requires the expenditure of ATP, we also investigated whether any alterations exist in respect to cellular ATP contents. Our results showed that neither the proteasomal activity nor the ATP status was significantly different between Ag8AHÀ and Ag8AH+ cells (data not shown). In addition, Ag8AH+ versus Ag8AHÀ subclones traverse through cell cycle with similar kinetics (Fig. 2A) . Interestingly, in the presence of bortezomib, G 2 arrest occurs earlier and is more pronounced in Ag8AH+ compared with Ag8AHÀ cells (Fig. 2A) .
The following figures show experiments using the two subclones Ag8AHÀ (Ag8AH.12) and Ag8AH+ (Ag8AH.1) as shown in Fig. 1A ; however, similar results were obtained using other AH-chainnegative as well as AH-chain-positive subclones (data not shown).
We investigated by three independent assays whether decreased viability in bortezomib-treated Ag8AH+ compared with Ag8AHÀ cells is due to induction of apoptosis. First, the frequency of apoptotic and necrotic cells in the presence of bortezomib was determined using Annexin V-FITC and propidium iodide staining. The percentages of Annexin V-FITC-positive/propidium iodidenegative apoptotic cells were significantly higher in Ag8AH+ compared with Ag8AHÀ subclones (Fig. 2B) . In addition, the percentages of Annexin V-FITC/propidium iodide double-positive cells, representing primary or secondary necrotic cells, were strongly increased in Ag8AH+ compared with Ag8AHÀ cells (Fig. 2B) . Second, induction of apoptotic cell death by bortezomib was verified by measuring the mitochondrial membrane potential w using the fluorescent dye DiOC 6 . The mean fluorescence intensity was markedly lower in Ag8AH+ cells, again confirming that bortezomib preferentially induced apoptosis in Ag8 cells expressing AH-chains (Fig. 2C) . Third, there was significantly higher caspase-3/7 activity in Ag8AH+ compared with Ag8AHÀ subclones (Fig. 2D) . To evaluate the functional importance of caspase activation for bortezomibinduced apoptosis, we analyzed the influence of the pan-caspase inhibitor zVAD-FMK. As shown in Fig. 2E , zVAD-FMK significantly interferes with bortezomib-triggered cell death in Ag8AH+ subclones. These results based on the analyses of various subclones with and without AH-chain expression, all derived from the same parental AH-chain-transfected Ag8 clone, and therefore, only differing in immunoglobulin expression, further confirmed that immunoglobulin synthesis is sufficient to confer increased sensitivity towards apoptosis upon proteasome inhibition.
Bortezomib induces proapoptotic CHOP in Ag8MH+ cells. Next, we wanted to further investigate the mechanism of apoptosis induction by bortezomib in Ag8AH+ cells. Recently, it has been shown that inhibition of the proteasome induces UPR. Hence, we tested whether bortezomib triggers ER stress in Ag8 subclones, leading to activation of terminal UPR and apoptosis. We analyzed prominent UPR components, such as BiP, XBP-1, CHOP, and caspase-12, known to be activated by classic inducers of UPR such as the glycosylation inhibitor tunicamycin.
First, we evaluated the activation of the prosurvival chaperone BiP over time in bortezomib-treated Ag8AHÀ compared with Ag8AH+ cells. Immunoblotting showed that the basal levels of BiP were already very high, and neither tunicamycin nor bortezomib further increased protein levels of BiP in Ag8AHÀ and Ag8AH+ cells (Fig. 3A) . Next, we studied the influence of bortezomib on the expression of XBP-1, a transcription factor inducing UPR components including chaperones. Upon ER stress, XBP-1 mRNA is spliced by the stress transmembrane kinase/RNase IRE1 to generate a transcript encoding a XBP-1 protein with higher transactivator activity. This splicing event is a frameshift splicing resulting in the translation of a larger XBP-1 protein (28) . Bortezomib treatment diminished the amount of spliced XBP-1 mRNA both in Ag8AHÀ and Ag8AH+ cells (Fig. 3B) , whereas the spliced and unspliced form of the XBP-1 protein markedly increased upon bortezomib treatment in all subclones (Fig. 3A) . This discrepancy is most likely explained by decreased proteolysis of XBP-1 during proteasome blockade, as described previously (29) .
Next, we investigated whether bortezomib induces UPR proteins involved in mediating apoptosis. Overexpression of CHOP (30), along with activation of caspase-12 (31) , is proposed to foster apoptotic processes within the UPR. Bortezomib treatment of Ag8 cells resulted in a marked induction of CHOP at 8 h (Fig. 3A) . Interestingly, in Ag8AH+ cells, CHOP accumulated earlier (4 h) and to much higher levels as in Ag8AHÀ cells (Fig. 3A) . Further results showed that bortezomib induced caspase-12 activation only in Ag8AH+ cells, as evidenced by detection of cleavage products derived from the 60 kDa precursor form (Fig. 3C) . These data indicate that proapoptotic signals are triggered by overexpression of CHOP and caspase activation preferentially in Ag8AH+ cells.
Bortezomib modulates the Bcl-2/Bax ratio in favor of proapoptotic Bax in Ag8MH+ cells. It has been reported that CHOP down-regulates antiapoptotic Bcl-2 (32). Moreover, both Bcl-2 and the proapoptotic Bcl-2 family member Bax have been shown to be associated with the ER, suggesting the involvement in ER stress-induced cell death (33) . Therefore, we analyzed whether bortezomib treatment, which we have already found to increase CHOP, may also alter the Bcl-2/Bax ratio.
Quantitative real-time PCR analyses revealed a reduction of Bcl-2 mRNA in Ag8AHÀ cells upon bortezomib treatment; in Ag8AH+ subclones, there was no marked change of Bcl-2 mRNA levels observed (Fig. 4A) . However, Bcl-2 protein levels decreased to a similar extent in both cell lines at 4 and 8 h after treatment with bortezomib (Fig. 4B) .
In Ag8AHÀ cells, the mRNA levels of the proapoptotic factor Bax slightly decreased upon bortezomib treatment. In contrast, in Ag8AH+ cells, Bax mRNA levels increased, especially 2 h after bortezomib treatment (Fig. 4A) . In agreement with real-time PCR results, Bax protein concentrations decreased in Ag8AHÀ cells but accumulated over a period of 8 h after addition of bortezomib in Ag8AH+ cells (Fig. 4B) . In summary, the ratio of Bcl-2/Bax proteins as calculated by densitometric analyses (data not shown) was lower in Ag8AH+ cells compared with Ag8AHÀ cells 8 h after bortezomib treatment. This differential regulation by bortezomib of antiapoptotic versus proapoptotic Bcl-2 family members may contribute to increased apoptotic cell death in Ag8AH+ compared with Ag8AHÀ cells.
Bortezomib alters activity of the transcription factors NF-KB and activator protein-1. Because it is generally assumed that the antitumor effect of bortezomib is, at least partially, due to inhibition of NF-nB (34), we analyzed the basal NF-nB activity in Ag8 myeloma cells. Nuclear extracts prepared from bortezomib-treated Ag8AH+ and Ag8AHÀ cells were subjected to EMSA to quantify NF-nB DNA-binding activity. In 
www.aacrjournals.org repeated experiments we did not find major differences in DNA binding ( Fig. 5A and B) . If at all, upon bortezomib treatment, there was a trend towards a decreased NF-nB DNA-binding activity in Ag8AHÀ subclones but an increased NF-nB activity in Ag8AH+ (Fig. 5A and B) . However, NF-nB DNA-binding activity does not necessarily reflect transcriptional activity, which is also regulated by other mechanisms including complex composition, acetylation, and phosphorylation events. Therefore, we analyzed InBa mRNA levels, which are strongly induced by NF-nB activation (35) . Relative InBa mRNA levels dropped in both Ag8 subclones upon bortezomib treatment (Fig. 5C) , indicating that NF-nB transcriptional activity is reduced at a similar degree in Ag8AH+ and Ag8AHÀ subclones. Hence, preferential blockade of the survival factor NF-nB does not account for the increased sensitivity of Ag8AH+ cells towards bortezomib. It remains unclear which mechanisms cause the discrepancy between DNAbinding activity and transcriptional activity of NF-nB under conditions of proteasome blockade.
Interestingly, DNA-binding activity of the transcription factor Oct-1 slightly increased in Ag8AH+ and Ag8AHÀ subclones upon bortezomib treatment (Fig. 5A and B) , which might be due to stabilization of the transcription factor because of reduced proteasomal degradation. However, DNA-binding activity of the transcription factor activator protein-1 (AP-1), which is involved in Figure 4 . Bortezomib modulates expression of Bcl-2 family members. A, quantitative real-time PCR analysis of total RNA isolated from Ag8AHÀ/+ subclones treated with 1 Amol/L bortezomib for indicated time intervals. As control, cells were treated with 5 Ag/mL tunicamycin (tun ) for 6 h. Relative Bcl-2 and Bax mRNA levels of bortezomib-treated Ag8AHÀ/+ subclones normalized to h-actin mRNA levels, which served as internal control. cDNA from untreated cells served as reference control. The comparative C t (DDC T ) method for relative quantification of gene expression was used. PCR analysis was done in triplicates. One representative data set of at least two independent experiments. B, Western blot analysis of total cell lysates from Ag8AHÀ/+ subclones, cultured for the indicated time intervals in the presence of 1 Amol/L bortezomib. Tunicamycin-treated cells served as control. Cell lysates were separated by SDS-PAGE on a 12.5% polyacrylamide gel. Immunoblotting was done using anti-Bcl-2 and anti-Bax antibodies. The upper bands detected by the Bcl-2 antibody are proposed to be phosphorylated forms of Bcl-2, and the lower one, running at 23 kDa, corresponds to a cleaved form of Bcl-2. Anti-actin antibody staining served as loading control. + subclones (Fig. 5A  and B) . These data may indicate a role of ER overload/stress for induction of AP-1.
IgG-derived DRiPs accumulate in response to proteasome inhibition. It has been shown that due to failure at translation or posttranslational processes, f30% of newly synthesized proteins are defective (26, 37) . In myeloma cells, the relatively high expression levels of immunoglobulin should concomitantly result in the formation of a substantial number of ER-resident DRiPs, which ultimately have to be degraded by the ubiquitin-proteasome system. Therefore, proteasome inhibition should cause an accumulation of DRiPs and other unfolded proteins responsible for induction of UPR-initiated apoptosis.
To analyze IgG DRiP formation in a human non-transfected myeloma cell line, we did short-term pulse-chase experiments using JK-6L cells. To rescue defective ribosomal products from proteasomal degradation, we used a combination of two proteasome inhibitors (lactacystin and MG-132), which in previous DRiP pulse-chase experiments have been shown to efficiently and rapidly shut down the activity of the 26S proteasome. 35 S-methioninelabeled IgG molecules were recovered from the soluble fraction by immunoprecipitation using antihuman IgG antibodies. Upon proteasome inhibition, the recovery of radiolabeled IgG heavy chains was increased by f30%, reaching its maximum at 5 min after pulse radiolabeling (Fig. 6A) . These results are consistent with an accumulation of IgG-DRiPs caused by proteasome inhibition.
Discussion
Bortezomib was previously shown to target malignant myeloma cells through induction of apoptosis, probably by blocking NF-nB activation, which mediates survival and resistance to chemotherapy and radiotherapy (2, 6, 7, 38, 39) . However, testing numerous cell lines for their basal NF-nB activity and their sensitivity to proteasome inhibition, we previously observed that high levels of protein synthesis were more predictive for proteasome inhibitor-induced apoptosis than NF-nB activity (data not shown). In addition, previous reports evidenced that proteasome inhibition has more profound effects on myeloma cells than just NF-nB inhibition (29, 40, 41) , indicating mechanisms beyond NF-nB blockade.
Extensive protein synthesis within the secretory ER pathway is an extraordinary feature of plasma cells and their malignant counterparts, myeloma cells. In the case of secreted proteins, such as immunoglobulin, DRiPs should initially arise in the ER, whereas DRiP degradation is proposed to take place in the cytoplasmic proteasomes. Therefore, we suggest that accumulation of unfolded proteins, predominantly DRiPs, within the ER leads to UPR activation, resulting in inhibition of protein synthesis and induction of ER chaperones to enhance folding and to prevent aggregation of nascent secretory proteins. Unfolded proteins that cannot be correctly folded are redirected to the cytoplasm by the action of ERAD and degraded by the 26S proteasome (42) . Blockade of proteasomes inhibits consequently ERAD-mediated export of unfolded proteins into the cytoplasm, thereby increasing UPR and ER overload (42) . Whereas UPR activation is essential in plasma cell physiology and survival (14-16), prolonged overwhelming UPR activation causes apoptosis. Hence, myeloma cells producing enormous numbers of immunoglobulin should accumulate deleterious amounts of unfolded proteins under condition of proteasome inhibition.
In the presence of bortezomib, we observed increased intracellular amounts of AH-chains, which were predominantly ubiquitinylated, indicating a proteasome-dependent degradation of unfolded AH-chains (data not shown). Other groups also provided Figure 5 . Influence of bortezomib on nuclear DNA-binding activity of the transcription factors NF-nB and AP-1 is dependent on AH-chain expression status. A, EMSA was done with nuclear extracts (10 Ag) prepared from Ag8AHÀ/+ cells treated with 1 Amol/L bortezomib for indicated time intervals. NF-nB, Oct-1, and AP-1 DNA-binding activity was analyzed using 32 P-labeled oligonucleotide probes containing specific binding sites. The results of the blocking experiment with unlabeled double-stranded oligonucleotides (+Inh ; showing blocking) or a respective mutant variant (Mut ) that did not suppress specific signals as well as sample without competing oligonucleotide (ÀInh ). As further control, gel was loaded with free labeled probes. B, quantification of NF-nB, Oct-1, and AP-1 activity plotted in phosphoimager units (PLS). Representative data from one of two independently done experiments. C, determination of transcriptional InBa activity. Quantitative real-time PCR analysis of total RNA isolated from Ag8AHÀ/+ subclones treated with 1 Amol/L bortezomib for indicated time intervals. Relative InBa mRNA levels of bortezomib-treated Ag8AHÀ/+ subclones normalized to h-actin mRNA levels, which served as internal control. cDNA from untreated cells served as reference control. The comparative C t (DDC T ) method for relative quantification of gene expression was used. Columns, mean from triplicates; bars, SD. P V 0.01 versus 0 h controls.
evidence that non-secreted ER-retained IgL-and AH-chains are degraded by the ubiquitin-proteasome pathway (43, 44) .
Thus far, all DRiPs assigned to a defined protein were either derived from infected or transfected cells overexpressing viral or recombinant proteins but not from endogenously expressed proteins (26, 45, 46) . Pulse-chase analyses revealed an accumulation of 35 S-methionine-labeled IgG in the cytoplasmic fractions. Accumulation of DRiPs due to proteasome inhibition may be an important mechanism of bortezomib-mediated cell death, targeting primarily cells with high protein synthesis. Of course, this represents not the only cytotoxic mechanism of bortezomib. For instance, other tumor cells may be primarily eliminated due to their dependence on NF-nB activation.
A very recent report comparing two cell lines from different patients found an increased sensitivity towards bortezomib in the cell line containing higher concentrations of IgE chains associated with activation of the terminal UPR (41) . To investigate if immunoglobulin synthesis itself sensitizes cells to proteasome inhibitor-induced cell death, we systematically investigated subclones of the same human myeloma cell line JK-6L, only varying in respect to the amount of IgG production. Consistent with our hypothesis, increasing levels of IgG rendered cells more susceptible to bortezomib-induced cell death.
To confirm the effect of immunoglobulin chain expression on sensitivity towards bortezomib, the non-immunoglobulin-producing murine myeloma cell line Ag8.H was stably transfected with a AH-chain expression plasmid. Expression of AH-chain resulted in drastically increased sensitivity to proteasome inhibition. Most likely, increased synthesis of ER proteins generally leads to increased susceptibility against proteasome inhibitors, as evidenced by transgenic expression of the transmembrane protein Iga.
To exclude transfection artifacts, subclones of the Ag8AH clone were established. In addition, Ag8AH+ subclones were much more sensitive to proteasome inhibitors compared with Ag8AHÀ subclones. Cell death induced by bortezomib was predominantly apoptotic, both in Ag8AH+ and Ag8AHÀ cells as shown by Annexin V-FITC/propidium iodide staining, decreased mitochondrial membrane potential, and caspase activation. As expected, the pancaspase inhibitor zVAD-FMK significantly delayed onset of cell death. 35 S-radioactivity of Igg heavy chains was quantified using phosphoimaging and plotted as percentage of initial incorporation. B, model of bortezomib-induced apoptosis in myeloma cells. In cells secreting large amounts of immunoglobulin, defective ribosomal products and other unfolded proteins arise, which get ubiquitinylated and are normally degraded by the 26S proteasome complex. Proteasome inhibitors, such as bortezomib, block the enzymatic activity of proteasomes, thereby preventing disposal of misfolded proteins and NF-nB activation. Consequently, accumulation of unfolded proteins/DRiPs within the cell along with weakened activation of the survival factor NF-nB, which is otherwise strongly induced by ER overload, leads to apoptosis.
Reactive oxygen species (ROS) are involved in the process of bortezomib-induced apoptotic cell death (47) . As described, ROS, produced by misfolded proteins (oxidation and reduction of disulfide bonds), accumulate during prolonged UPR and contribute to cell death (48) . We observed a significantly higher increase of ROS by bortezomib treatment in Ag8AH+ compared with Ag8AHÀ subclones, linking increased ROS production and susceptibility to cell death to immunoglobulin synthesis (data not shown). In addition, elimination of ROS by antioxidants, such as Nacetylcystein, markedly reduced bortezomib-induced cell death in Ag8AH+ cells (data not shown).
In spite of the high number of subclones analyzed, we could not identify any IgG-negative JK-6L subclones, indicating that immunoglobulin expression is crucial for survival of plasma as well as myeloma cells, most likely by UPR-mediated expression of chaperones and autocrine growth factors such as IL-6 (14-16). Extensive studies have elucidated the relationship between the UPR and plasma cell differentiation (49) . The UPR-induced transcription factors XBP-1 and ATF6 mediate the induction of UPR target genes such as ER-resident chaperones.
One major mechanism by which bortezomib induces apoptosis in Ag8 cells could be the induction of the terminal UPR pathway, driven by overwhelming accumulation of defective immunoglobulin chains in the ER. Previously published data have shown that bortezomib is able to induce ER stress in pancreatic cancer and myeloma cells (29, 40, 41) . To investigate whether proteasome inhibition activates UPR, and whether this depends on immunoglobulin synthesis, we analyzed the induction and activation status of prosurvival UPR components, such as BiP, and proapoptotic terminal UPR components, such as CHOP and caspase-12, in Ag8AHÀ versus Ag8AH+ subclones. Chaperones like BiP are highly constitutively expressed in plasma cells to ensure the secretory cell function. Our finding that BiP synthesis is not markedly altered in bortezomib-and tunicamycin-treated Ag8 cells suggests that BiP expression has already reached maximally high levels in these myeloma cells.
UPR-mediated cell survival or cell death is regulated by the balance of cytoprotective and proapoptotic factors (17) . Consistent with findings of other groups (40, 41, 50) , we showed that CHOP is strongly up-regulated in bortezomib-treated cells. Most importantly, our data revealed a faster and stronger induction of CHOP in Ag8AH+ compared with Ag8AHÀ cells. Hence, bortezomib causes a strong up-regulation of CHOP without an increase of BiP, thereby fostering apoptotic cell death by altering the ratio of these prosurvival and antisurvival factors.
One relevant target of CHOP is Bcl-2, whose expression is suppressed by CHOP (32). Bcl-2 protein levels were clearly reduced during incubation with bortezomib, but in Ag8AH+ cells, Bcl-2 protein expression partially recovered after 8 h, a fact that may reflect a block in proteasome-mediated degradation of Bcl-2 (51, 52) . Based on our findings, the previously observed bortezomibinduced reduction of Bcl-2 (53) may be, at least partially, mediated by increased CHOP levels.
The proapoptotic Bax, antagonizing Bcl-2, was induced on mRNA and protein level in bortezomib-treated Ag8AH+ but not in Ag8AHÀ cells. These data suggest transcriptional induction of Bax; however, we cannot exclude additional effects of bortezomib on proteasome-mediated degradation of Bax (54) . In Ag8AH+ cells, bortezomib modulates the Bcl-2 to Bax ratio in favor of the proapoptotic Bax, whereas in Ag8AHÀ cells, the Bcl-2 to Bax ratio is altered more in favor of the antiapoptotic Bcl-2. In summary, bortezomib-induced proapoptotic factors, such as Bax, CHOP, and caspases, may dominate over antiapoptotic factors like Bcl-2 in tilting the balance towards apoptosis, especially in immunoglobulinsynthesizing cells.
Inhibition of NF-nB activation by bortezomib is generally considered as a major mechanism of the proapoptotic effects of proteasome inhibition on tumor cells (7) . In addition, UPR and ER overload have been shown to induce activation of NF-nB (55, 56) . As expected, we did not observe a marked increase of NF-nB DNAbinding activity under conditions of bortezomib-induced ER stress, most likely due to simultaneous blockade of proteasome-dependent InB degradation. Monitoring InBa mRNA expression, which is highly dependent on NF-nB activity, even indicated a marked reduction in NF-nB transcriptional activity in both Ag8 subclones. The discrepancy in between just slightly changed NF-nB DNA-binding activity and drastically reduced transcriptional activity remains still elusive but might be due to altered posttranslational modifications and coactivator recruitment to NF-nB. We conclude that inhibition of NF-nB activation is not the crucial factor, which explains the differential sensitivity of Ag8AH+ versus Ag8AHÀ subclones to proteasome inhibition: NF-nB DNA-binding and transcriptional activity were similarly affected in Ag8AHÀ and Ag8AH+ cells, if at all, there was a even stronger inhibition in Ag8AHÀ clones. Nevertheless, inhibition of NF-nB activity may contribute to apoptosis.
The transcription factor AP-1 was significantly induced in bortezomib-treated Ag8AH+ cells. AP-1 is induced by the UPR kinase IRE-1 via activation of c-Jun NH 2 -terminal kinase (JNK), which is known to mediate stress-induced apoptosis (36, 57) . Therefore, JNK/ AP-1 signaling may also contribute to bortezomib-induced cell death.
This work shows that myeloma cells producing high amounts of immunoglobulin are more susceptible to apoptosis by agents, such as bortezomib, that evoke overwhelming ER stress by inhibiting the degradation of unfolded proteins, including DRiPs. Simultaneously, bortezomib interferes with ER overload-mediated activation of NF-nB, which normally counteracts ER stress-induced apoptosis (Fig. 6B) .
Our findings that sensitivity towards proteasome inhibition is primarily dependent on the extent of immunoglobulin synthesis have important implications for the therapeutic use of bortezomib and other proteasome inhibitors. We postulate that tumors synthesizing high amounts of proteins, especially secreted ones, represent primary targets of proteasome inhibitors. Down-regulation of protein biosynthesis or increase of protein folding enzymes/ chaperones could represent a novel mechanism for partial resistance towards bortezomib. However, a complete cessation of immunoglobulin production may be barely observed because a significant level of UPR activation seems to be important for plasma and myeloma cell physiology and survival (14) (15) (16) . Moreover, agents influencing protein folding and DRiP rate may modulate the sensitivity of cells towards proteasome inhibitors and augment the antimyeloma activity of bortezomib.
